Table 2 Demographic and clinical characteristics of patients.

From: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

 

Men N = 294

Women N = 218

Overall N = 512

T-test or Chi-squared test p-value

Age

   

0.1074

Mean (SD)

63.8 (9.3)

62.5 (9.8)

63.3 (9.5)

 

Median (Q1–Q3)

64.5 (58.7–70.9)

63.2 (56.4–69.8)

64.0 (57.4–70.7)

 

Min–Max

25.1–82.3

34.3–81.9

25.1–82.3

 

Performance status - n (%)

   

0.7473

0

283 (96.3)

211 (96.8)

494 (96.5)

 

1

11 (3.7)

7 (3.2)

18 (3.5)

 

Tumor site

   

0.4391

Single site

279 (94.9)

210 (96.3)

489 (95.5)

 

Multiple site

15 (5.1)

8 (3.7)

23 (4.5)

 

Single site specification - n (%)

   

0.4849

Ascending colon

74 (26.5)

64 (30.5)

138 (28.2)

 

Hepatic flexure

13 (4.7)

14 (6.7)

27 (5.5)

 

Trasverse colon

15 (5.4)

17 (8.1)

32 (6.5)

 

Splenic flexure

13 (4.7)

11 (5.2)

24 (4.9)

 

Descending colon

46 (16.5)

27 (12.9)

73 (14.9)

 

Sigmoid colon

77 (27.6)

54 (25.7)

131 (26.8)

 

Sigmoid-rectum colon

41 (14.7)

23 (11.0)

64 (13.1)

 

Missing

15

8

23

 

Tumor side - n (%)

   

0.0426

Right sides

102 (34.7)

96 (44.0)

198 (38.7)

 

Left sides

178 (60.5)

115 (52.8)

293 (57.2)

 

Multiple side*

14 (4.8)

7 (3.2)

21 (4.1)

 
  1. *This category includes patients with both right and left tumor sides. The statistical test was performed excluding patients with multiple sided tumor.